JP2019507185A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507185A5
JP2019507185A5 JP2018559177A JP2018559177A JP2019507185A5 JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5 JP 2018559177 A JP2018559177 A JP 2018559177A JP 2018559177 A JP2018559177 A JP 2018559177A JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
phenyl
membered heterocyclic
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018559177A
Other languages
English (en)
Japanese (ja)
Other versions
JP7098214B2 (ja
JP2019507185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015749 external-priority patent/WO2017136309A1/en
Publication of JP2019507185A publication Critical patent/JP2019507185A/ja
Publication of JP2019507185A5 publication Critical patent/JP2019507185A5/ja
Application granted granted Critical
Publication of JP7098214B2 publication Critical patent/JP7098214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018559177A 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用 Active JP7098214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662289463P 2016-02-01 2016-02-01
US62/289,463 2016-02-01
US201662398872P 2016-09-23 2016-09-23
US62/398,872 2016-09-23
PCT/US2017/015749 WO2017136309A1 (en) 2016-02-01 2017-01-31 USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Publications (3)

Publication Number Publication Date
JP2019507185A JP2019507185A (ja) 2019-03-14
JP2019507185A5 true JP2019507185A5 (https=) 2020-03-12
JP7098214B2 JP7098214B2 (ja) 2022-07-11

Family

ID=58018271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559177A Active JP7098214B2 (ja) 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用

Country Status (11)

Country Link
US (1) US11357777B2 (https=)
EP (1) EP3411026B1 (https=)
JP (1) JP7098214B2 (https=)
KR (1) KR20180104123A (https=)
CN (2) CN108697678A (https=)
AU (1) AU2017216429B2 (https=)
BR (1) BR112018015718A2 (https=)
CA (1) CA3012001A1 (https=)
IL (1) IL260701B (https=)
MX (1) MX386216B (https=)
WO (1) WO2017136309A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194386A2 (en) * 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
AU2017216429B2 (en) 2016-02-01 2022-10-06 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド S1p1活性を調節するための化合物およびその使用法
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
KR20250141845A (ko) * 2018-07-11 2025-09-29 티센토 쎄라퓨틱스 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
WO2020011804A1 (en) * 2018-07-12 2020-01-16 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
CN114555076B (zh) * 2019-10-18 2024-02-02 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
CA3170507A1 (en) * 2020-02-21 2021-08-26 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
WO2023143424A1 (zh) * 2022-01-27 2023-08-03 四川海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2011056511A2 (en) * 2009-10-26 2011-05-12 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
HRP20150987T1 (hr) 2010-05-26 2015-10-23 Adverio Pharma Gmbh UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CN102164320B (zh) 2011-04-11 2016-06-22 北京数字太和科技有限责任公司 一种改进的基于条件接收技术的终端
EA033168B1 (ru) * 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US9663527B2 (en) * 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
PL3172202T3 (pl) * 2014-07-22 2020-07-13 Boehringer Ingelheim International Gmbh Heterocykliczne kwasy karboksylowe jako aktywatory rozpuszczalnej cyklazy guanylanowej
CA3006746C (en) * 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
AU2017216429B2 (en) 2016-02-01 2022-10-06 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
EP3458063A4 (en) 2016-05-18 2020-02-26 Merck Sharp & Dohme Corp. METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES

Similar Documents

Publication Publication Date Title
JP2019507185A5 (https=)
DK2041102T3 (en) Inhibitors of human protein tyrosine phosphatase and methods of use
AU2006245676B2 (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
IL186750A (en) Patridines, their uses in preparing HCV replication inhibitors, their compositions and combinations
AU2018233975A1 (en) Pharmaceutical compositions for combination therapy
JP2019502686A5 (https=)
JP2018501276A5 (https=)
RU2002129569A (ru) Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора
JP2008509187A5 (https=)
JP2018532720A (ja) 線維症の治療のためのセニクリビロック併用療法
RU2009121775A (ru) Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное
JP2003515523A5 (https=)
RU2006136881A (ru) Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv
RU2008141511A (ru) Конденсированные гетероциклические соединения и их применение в качестве модуляторов mglur5
JP2016512547A (ja) 線維症疾患の治療のための化合物
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
AU2005282290B2 (en) Combination of organic compounds
BRPI0710675A2 (pt) uso de inibidores de c-src em combinação com um composto pirimidilaminobenzamida para o tratamento de leucemia
JP2024507414A5 (https=)
JP2021518379A5 (https=)
WO2010000030A1 (en) Thiazopyrimidinones and uses thereof
JP2007533730A (ja) 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法
EP1742633A2 (en) Use of c-kit inhibitors for treating fibrosis
CN112384214A (zh) 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑
RU2019101226A (ru) Ингибиторы wnt для применения при лечении фиброза